DMRA insider transactions
Damora Therapeutics Inc. (DMRA) Form 4 insider transactions - real-time wire coverage of every officer, director, and 10% owner trade.
DMRA insiders
Everyone who has filed a Form 3, 4, 5 or 144 at Damora Therapeutics Inc., latest first. Follow anyone to get their next filing.
- Jennifer JarrettDirector, President and CEO, since March 2026+$253K
- Andrew ChengDirector, since August 2026
- Garrett WinslowGeneral Counsel, since May 2021+$14.6K-$16.3K
- Brian BurkavageSVP, Finance, since May 2026
- Cameron TurtleDirector, since March 2026
- Michael LandsittelDirector, since March 2026
- Fairmount Funds Management LLCDirector, 10% owner, since November 2025
- Christopher W. CainDirector, since November 2025
- Julianne BrunoDirector, since November 2025
- Sherwin SattarzadehChief Operating Officer, since January 2026
- L. Becker HewesChief Medical Officer, since January 2026
- Hans T. SchambyeChief Executive Officer, Director+$41.8K-$25K
- Lori FirmaniChief Financial Officer, since August 2024-$4,858
- Dallas Jayson Donald AlexanderDirector
- David ShapiroDirector
- Amit MunshiDirector
- Anne PrenerDirector
- Carl GoldfischerDirector
- Amy B WechslerDirector, since October 2024
- Matthew KronmillerEVP Strategy and CBO, since October 2024
- Jonathan FreveChief Financial Officer+$41.4K
- Orbimed Advisors LLC10% owner-$2.3M
- Chau Quang KhuongDirector
- Stephanie OestreichOfficer, since January 2022
- Anders PedersenOfficer
- Bertil LindmarkOfficer+$42.1K
Recent Form 3, 4, and 5 filings for DMRA
- Director, President and CEO Jarrett Jennifer bought $252,875 worth of Ordinary Shares (12,500 units at $20.23), increasing direct ownership by 2% to 512,500 units (SEC Form 4)4 - Damora Therapeutics, Inc. (0001800315) (Issuer)
- SEC Form 4 filed by Director Cheng Andrew4 - Damora Therapeutics, Inc. (0001800315) (Issuer)
- SEC Form 3 filed by new insider Cheng Andrew3 - Damora Therapeutics, Inc. (0001800315) (Issuer)
- General Counsel Winslow Garrett converted options into 680 shares and sold $7,345 worth of shares (245 units at $29.98), increasing direct ownership by 23% to 2,289 units (SEC Form 4) (for withholding tax)4 - Damora Therapeutics, Inc. (0001800315) (Issuer)
- SEC Form 3 filed by new insider Burkavage Brian3 - Damora Therapeutics, Inc. (0001800315) (Issuer)
- SEC Form 4 filed by Jarrett Jennifer4 - Damora Therapeutics, Inc. (0001800315) (Issuer)
- SEC Form 3 filed by new insider Jarrett Jennifer3 - Damora Therapeutics, Inc. (0001800315) (Issuer)
- SEC Form 4 filed by Winslow Garrett4 - Damora Therapeutics, Inc. (0001800315) (Issuer)
- SEC Form 4 filed by Turtle Cameron4 - Damora Therapeutics, Inc. (0001800315) (Issuer)
- SEC Form 4 filed by Landsittel Michael4 - Damora Therapeutics, Inc. (0001800315) (Issuer)
- SEC Form 4 filed by Fairmount Funds Management Llc4 - Damora Therapeutics, Inc. (0001800315) (Issuer)
- SEC Form 4 filed by Cain Christopher W.4 - Damora Therapeutics, Inc. (0001800315) (Issuer)
- SEC Form 4 filed by Bruno Julianne4 - Damora Therapeutics, Inc. (0001800315) (Issuer)
- SEC Form 3 filed by new insider Turtle Cameron3 - Damora Therapeutics, Inc. (0001800315) (Issuer)
- SEC Form 3 filed by new insider Landsittel Michael3 - Damora Therapeutics, Inc. (0001800315) (Issuer)